Stay updated with breaking news from Marca Riedl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacksZUG, Switzerland, Feb. 22, 2024 -- Pharvaris , a...
ZUG, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today
The randomized, double-blind, event-driven crossover study evaluated sebetralstat, an oral plasma kallikrein inhibitor, vs placebo for the on-demand treatment of HAE.
ZUG, Switzerland, Jan. 26, 2024 -- Pharvaris , a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema attacks, today...
Primary endpoint met: deucrictibant significantly reduced attack rate The primary endpoint of the CHAPTER-1 study measured the time-normalized number of investigator-confirmed HAE attacks during the treatment period. The monthly attack rate was reduced by 84.5% (p=0.0008) compared to placebo in participants who received 40 mg/day of deucrictibant. Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to place